Skip to main content

Table 2 Treatment at the end of follow-up (death or the end of the study)

From: Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents

Treatment Number (%) of patients
All Group 1 Group 2 Group 3 Group 4
Epoprostenol* 22 (54) 13 (32) 9 (22) 0 (0) 0 (0)
ERA 9 (22) 1 (2) 0 (0) 4 (10) 4 (10)
PDE5I 14 (34) 3 (7) 1 (2) 4 (10) 6 (15)
Beraprost 3 (7) 0 (0) 0 (0) 1 (2) 2 (4)
  1. Variables are number (%) of patients. ERA: endothelin receptor antagonist, PDE5I: phosphodiesterase 5 inhibitor. Some patients received more than one of the drugs. *p < 0.001, p = 0.035.